Compared with that of chemotherapy, PD-1/PD-L1 inhibitors were associated with a lower risk of myalgia (RR: 0.56, 95% CI: 0.45–0.70), but compared with other subgroups, the result was in contrary, as is shown in Figure 6. This evidence concerns the gene RPL17 and Myalgia.